Recent Finacing
Recent Raise
Anaveon is a Basel-based clinical-stage biopharma developing selective IL-2 receptor agonists (lead ANV419 in Phase I/II for solid tumors) and advancing preclinical cytokine-engineered programs.
Focus Areas
Recent Investors
Valuation as of 02/27/2019
Total Raised
Funding rounds
Investors
See the team members at Anaveon.
